NMDA GluN2B Antagonists for Chronic Cough Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no known cure for chronic cough, and conventional treatments only alleviate symptoms, failing to address the underlying issue effectively.
Innovation Solution
Utilizing glutamate 2b receptor antagonists such as Ifenprodil and Radiprodil, either alone or in combination with other compounds, to treat or prevent cough by targeting the glutamate 2b receptor and sigma receptor 1, which are administered orally or intravenously in therapeutically effective amounts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chronic cough, then symptoms are temporarily alleviated, but the underlying issue is not effectively addressed and cough recurs
Solution Approach 1:
Instead of treating only the symptoms of chronic cough (as conventional treatments do), this invention inverts the approach by targeting the underlying pathological mechanisms through glutamate 2b receptor antagonists and sigma receptor agonists, which address the root cause of cough hypersensitivity and inflammation, thereby providing both symptom relief and prevention of recurrence
Solution Approach 2:
This invention changes the therapeutic parameters by introducing new drug targets (glutamate 2b receptors and sigma receptors) that were not previously addressed in cough treatment. By modulating these specific receptors, the treatment alters the physiological parameters of cough reflex sensitivity and airway inflammation, leading to more effective and durable symptom control
2Reliability
If new drug mechanisms are introduced to address underlying causes, then treatment effectiveness improves, but drug complexity and potential side effects increase
Solution Approach 1:
The patent leverages the multi-functionality of existing drugs by identifying compounds that can target multiple relevant receptors (glutamate 2b receptors and sigma receptors). This allows a single drug to address multiple aspects of the underlying cough pathology simultaneously, improving curative effectiveness without requiring complex combination therapies
Solution Approach 2:
The invention adapts drug mechanisms originally developed for other conditions (such as neuropathic pain or psychiatric disorders) and applies them to chronic cough treatment. By 'copying' the successful receptor-targeting approaches from other therapeutic areas, the patent achieves curative effectiveness for cough using established drug platforms with known safety profiles
Data Source
AI summary
The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.